Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 6.69
(-3.04%)
CNY 6.69
(-3.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 693.51 Million CNY | -3.72% |
| 2022 | 720.32 Million CNY | -31.76% |
| 2021 | 1.05 Billion CNY | -14.62% |
| 2020 | 1.23 Billion CNY | 106.19% |
| 2019 | 599.6 Million CNY | -13.1% |
| 2018 | 689.96 Million CNY | 95.79% |
| 2017 | 352.39 Million CNY | 101.87% |
| 2016 | 174.56 Million CNY | -22.06% |
| 2015 | 223.98 Million CNY | 20.61% |
| 2014 | 185.7 Million CNY | -19.64% |
| 2013 | 231.09 Million CNY | 79.61% |
| 2012 | 128.66 Million CNY | 11.08% |
| 2011 | 115.82 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 349.92 Million CNY | -37.12% |
| 2024 Q1 | 569.81 Million CNY | -17.84% |
| 2024 Q2 | 556.52 Million CNY | -2.33% |
| 2023 Q4 | 693.51 Million CNY | -9.72% |
| 2023 FY | 693.51 Million CNY | -3.72% |
| 2023 Q3 | 768.21 Million CNY | 4.37% |
| 2023 Q1 | 795.86 Million CNY | 10.49% |
| 2023 Q2 | 736.04 Million CNY | -7.52% |
| 2022 Q4 | 720.32 Million CNY | 21.37% |
| 2022 Q2 | 765.71 Million CNY | -22.96% |
| 2022 FY | 720.32 Million CNY | -31.76% |
| 2022 Q3 | 593.47 Million CNY | -22.49% |
| 2022 Q1 | 993.93 Million CNY | -5.84% |
| 2021 Q1 | 1.23 Billion CNY | -0.05% |
| 2021 Q3 | 1.22 Billion CNY | -10.26% |
| 2021 FY | 1.05 Billion CNY | -14.62% |
| 2021 Q4 | 1.05 Billion CNY | -13.79% |
| 2021 Q2 | 1.36 Billion CNY | 10.41% |
| 2020 FY | 1.23 Billion CNY | 106.19% |
| 2020 Q1 | 642.01 Million CNY | 7.07% |
| 2020 Q2 | 632.01 Million CNY | -1.56% |
| 2020 Q3 | 691.01 Million CNY | 9.34% |
| 2020 Q4 | 1.23 Billion CNY | 78.92% |
| 2019 FY | 599.6 Million CNY | -13.1% |
| 2019 Q3 | 843.78 Million CNY | 27.19% |
| 2019 Q4 | 599.6 Million CNY | -28.94% |
| 2019 Q2 | 663.41 Million CNY | 11.08% |
| 2019 Q1 | 597.24 Million CNY | -13.44% |
| 2018 Q1 | 333.2 Million CNY | -5.45% |
| 2018 FY | 689.96 Million CNY | 95.79% |
| 2018 Q4 | 689.96 Million CNY | 97.06% |
| 2018 Q3 | 350.12 Million CNY | -19.07% |
| 2018 Q2 | 432.61 Million CNY | 29.83% |
| 2017 Q2 | 219.57 Million CNY | 51.66% |
| 2017 FY | 352.39 Million CNY | 101.87% |
| 2017 Q1 | 144.77 Million CNY | -17.06% |
| 2017 Q4 | 352.39 Million CNY | 39.19% |
| 2017 Q3 | 253.17 Million CNY | 15.3% |
| 2016 Q2 | 202.37 Million CNY | 22.07% |
| 2016 Q4 | 174.56 Million CNY | 24.04% |
| 2016 Q3 | 140.73 Million CNY | -30.46% |
| 2016 Q1 | 165.79 Million CNY | -25.98% |
| 2016 FY | 174.56 Million CNY | -22.06% |
| 2015 Q4 | 223.98 Million CNY | 1.84% |
| 2015 FY | 223.98 Million CNY | 20.61% |
| 2015 Q3 | 219.93 Million CNY | -9.31% |
| 2015 Q2 | 242.51 Million CNY | -32.34% |
| 2015 Q1 | 358.42 Million CNY | 93.01% |
| 2014 Q4 | 185.7 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 185.7 Million CNY | -19.64% |
| 2013 FY | 231.09 Million CNY | 79.61% |
| 2012 FY | 128.66 Million CNY | 11.08% |
| 2011 FY | 115.82 Million CNY | 0.0% |